Immix Biopharma is trading 5.3% lower at $12.15, with the decline appearing primarily tied to broader risk-off conditions as rising crude oil and Treasury yields pressure equity valuations. - Reversing its September 22 close of $12.83. - No fresh company-specific announcement was identified for September 23, 2026. - The Nasdaq Composite is down 1.05%; XBI is up 2.07%, with biotech outperforming.